Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (November 2024)
22 slides from Maat Pharma's investor presentation, November 2024
Slide 1: Enhancing Survival Through Innovative Immune Modulation
MaaT Pharma Enhancing Survival Through Innovative Immune Modulation K
Slide 2: Disclaimer
Disclaimer This document has been prepared by Maa Pharma (the “Company*) andis for informationandbackgroundpurposesonly. While the information contained herein has been preparedin good faith, neither the Company, nor its shareholders, directors, officers, agents, employees, or advisors give, have gi
Slide 3: Success in Refractory GVHD Will Pave the Way for Broad Therapeutic Advances
MaaT Pharma. November 2024 3 Success in Refractory GVHD Will Pave the Way for Broad Therapeutic Advances x Breakthrough advances of MaaT013 in GVHD ©) Recruitment completed for Phase 3 in aGvHD in Europe, expecting primary endpoint readout in January 2025 © Unprecedented data from Early Access Progr
Slide 4: Management Team
MaaT Pharma. November 2024 Bi A Management Team wt Y Th Hervé Affagard Eric Soyer Gianfranco Pittari, Carole Sian Crouzet Jonathan Chriqui, MD, PhD Schwintner, PhD PharmD Co-Founder & CEO Chief Financial Chief Medical Chief Technology Chief of Staff Chief Business Officer Officer Officer Officer . C
Slide 5: Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates
MaaT Pharma. Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates Native Ecosystem Driving near-term value with the donor-derived MET-N platform MaaTO13 © MaaT033 PROPRIETARY POOLING APPROACH microbiota Co-cultured Ecosystem Progressing next-generation co-cultured scalable MET-C plat
Slide 6: Improving Disease Outcomes Through Microbiome Repair: GVHD and Beyond
MaaT Pharma. Nov Improving Disease Outcomes Through Microbiome Repair: GVHD and Beyond / Multiple Drivers of Microbiome a Local and Systemic >) ; ( ° Disruption Zl LO Effects of Dysbiosis ( eee rlwobioths py +) ~~ ©) “\ A 7, _ + Antibiotics (©) Loss of Microbial Diversity (2) Rebuilding Gut Microbia
Slide 7: A Strong Pipeline With Multiple Near-Term Value Inflection Milestones
MaaT Pharma, November 2024 7 A Strong Pipeline With Multiple Near-Term Value Inflection Milestones x Program Indication Market potential Preclinical Phase] Phase 2 Phase 3 Status BUpcoming milestone ~250m€ Fully > . ze) ry MaaT013 aGvHD IL: 10k patients? I 32 ~~ recruited CCORR January 2026 ODDEMAYF
Slide 8: Program Overview
Program Overview eo @ @e@e8e#e8#8e#e8e#e2s2#28es #®@
Slide 9: Understanding and Addressing Acute Graft-versus-Host Disease (aGvHD)
Understanding and Addressing Acute Graft-versus-Host Disease (aGVvHD) — Asignificant complication following allogeneic hematopoietic stem cell transplantation (AlloHSCT) — It may occur in 50% of patients undergoing AlloHSCT, typically presenting within the first 100 days post-transplant la In aGvHD,
Slide 10: Unmet Medical Need: Acute Graft-versus-Host Disease (aGVHD)
MaaTO13 « aGvHD Unmet Medical Need: Acute Graft-versus-Host Disease (aGVHD) Resistant to Steroids and Ruxolitinib (3"¢ line of treatment) Treatment Paradigm oS) Corticosteroids are the 1° line of treatment, but approximately 50% of patients do not achieve a sustained response oS) Ruxolitinib is appr
Slide 11: Microbiome Modulation to Restore Immune Homeostasis and Gut Barrier Integrity
MaaTO13 « aGvHD November 2024 Microbiome Modulation to Restore Immune Homeostasis and Gut Barrier Integrity Restoration of barrier integrity’ ie Restoration of microbial ; — CG) q eee KE homeostasisand diversity ©) Eradication of MDRB (©) Pathobiont growth inhibition Production of immunity-regulatin
Slide 12: ARES, a Pivotal Phase 3 Trial to Treat aGVHD in 3rd Line
2024 2 ARES, a Pivotal Phase 3 Trial to Treat aAGVHD in 3°¢ Line Showing “high efficacy ARES * and low toxicity” as Concluded by the DSMB with Topline in January 2025 + jy Treatment Period DI, 5, 10 66 Patients with SR-Gl-aGvHD ° mo Dy 2 MaaTO013 administration 4th dose if relapse after response Inc
Slide 13: In 3rd Line, the EAP Data Confirms Frequent Responses to MaaT013
MaaTO13 « aGvHD In 3°¢ Line, the EAP Data Confirms Frequent Responses to MaaT0O13 Leading to Prolonged Survival MaaT013 in aGvHD is well tolerated with a favorable benefit / risk profile to date EAP: ARES like cohort - N=58, Gl-aGvHD: 3 Line GI-ORR - D28 Overall Survival Rate Patients (%) N=58 Survi
Slide 14: Unlocking the Potential of Checkpoint Inhibitors
MaaTO13 + IO- Melanoma Unlocking the Potential of Checkpoint Inhibitors: How Full-Ecosystem Gut Microbiome Overcomes Primary Resistance Immune Checkpoint Inhibitors (ICI) significantly improve outcomes in solid tumor patients Primary Resistance Rate to ICIs Lung Cancer (NSCLC) Gia 35-40 % > Urgent n
Slide 15: MaaT013 Evaluated in Phase 2a Randomized Multicenter Trial in Melanoma
November 2024 ais} MaaT013 Evaluated in Phase 2 Randomized, Multicenter Clinical Trialin Melanoma = * Phase 2a PICASSO trial, fully recruited Key study endpoints after 23 weeks of treatment: Investigator Sponsored Trial (Assistance Publique - Hopitaux de Paris) in collaboration with Institut Gustave
Slide 16: MaaT033: Phase 2b PHOEBUS Trial in allo-HSCT Patients
November 2024 16 MaaTO33: Phase 2b PHOEBUS Trial Exploring a Potential Adjunctive * Treatment for allo-HSCT Patients First positive DSMB (n=20*) in July 2024 - safety DSMB are planned every 6 months throughout the study — Next anticipated January 2025 Design p Primary endpoint: of MaaT033 in Study s
Slide 17: MaaT033: Targeting Amyotrophic Lateral Sclerosis Progression
a MaaT033 + ALS November 2024 7 MaaTO33: Targeting Amyotrophic Lateral Sclerosis Progression ENCALS {ASO * Amyotrophic Lateral Sclerosis (ALS) GE — Upto 15 patie i il ‘label, Phase 1 in Fi — Could affect up to 60,000 patients in US & EU by 2040! Coe eee ese Blice Cet iene Anes ts ye ce — Paralysis a
Slide 18: MET-C Product Generation Driven by Proprietary Predictive AI
>» >) MET-C+ ICl and more November 2024 18 MET-C Product Generation is Driven by MaaT Pharma’s Proprietary x Predictive Al, Eubiotic Score and in vitro and in vivo Validation Processes MaaT034 MaaT034 © & a @ (>) In silico (>) In vitro (>) HIT Products LEAD Products Candidate Products Upcoming Miles
Slide 19: Europe's Largest Specialized cGMP Manufacturing Facility for Microbiome Ecosystem Therapies
© AllMeT Europe’s Largest ‘ Specialized cGMP Manufacturing Facility for Microbiome Ecosystem Therapies A dedicated 1,600m? site (+17,000 sq ft), expandable, to support demands until 2034 for MET-N clinical and future commercial production, R&D, and clinical batches of MET- C products (MaaT034 & MaaT
Slide 20: Key Takeaways
Key Takeaways
Slide 21: Multiple Near-Term Value Inflection Milestones
MaaT Pharma, Multiple Near-Term Value Inflection Milestones Q42 2026+ MaaT013 (pooled pouch) * GvHD| EAP Update ASH24 * GvHD| ARES P3 G-LORR January 25 + lO Mela. | PICASSO P2a Results Q1.25 * GvHD|ARES Final Results (OS) H2 25 * GvHD| Filing to EMA MaaT033 (pooled capsule) + ALS |IASO Plb Results Q
Slide 22: Thank you
Thank you